InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
03 sept. 2024 07h30 HE
|
InflaRx N.V.
JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced...
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
08 août 2024 07h30 HE
|
InflaRx N.V.
Hosted research and development (R&D) event focused on the differentiation of INF904 and its potential in addressing significant unmet needs in inflammation & immunology (I&I)Initiation of...
InflaRx Hosts R&D Event Highlighting the Promise of INF904
05 juin 2024 12h00 HE
|
InflaRx N.V.
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential...
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
21 mai 2024 14h30 HE
|
InflaRx N.V.
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data...
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
30 août 2023 07h30 HE
|
InflaRx N.V.
MAA for vilobelimab was submitted in JulyMAA has been validated by EMA and is now under reviewRegulatory submission based on pivotal data from PANAMO Phase III trialCompany announces attendance at...
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update
10 août 2023 07h30 HE
|
InflaRx N.V.
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States • Oral C5aR inhibitor INF904 progressing in...
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
28 juin 2023 07h30 HE
|
InflaRx N.V.
Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug developmentDr. Chong to lead clinical development of InflaRx’s portfolio of C5a/C5aR...
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
21 juin 2023 07h00 HE
|
InflaRx N.V.
Gohibic is now commercially available for hospitals in the U.S.Gohibic can be used under an Emergency Use Authorization (EUA) granted by the FDA for treatment of certain critically ill COVID-19...
InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
11 mai 2023 07h30 HE
|
InflaRx N.V.
Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA) for Gohibic (vilobelimab) for treatment of critically ill COVID-19 patientsGohibic planned to be available to...
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
04 avr. 2023 14h55 HE
|
InflaRx N.V.
Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune responseFDA granted EUA based on Phase III...